Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health
Louise A. Swainson, … , Rafick-Pierre Sekaly, Joseph M. McCune
Louise A. Swainson, … , Rafick-Pierre Sekaly, Joseph M. McCune
Published February 1, 2022
Citation Information: JCI Insight. 2022;7(5):e153046. https://doi.org/10.1172/jci.insight.153046.
View: Text | PDF
Research Article AIDS/HIV Immunology

IFN-α blockade during ART-treated SIV infection lowers tissue vDNA, rescues immune function, and improves overall health

  • Text
  • PDF
Abstract

Type I IFNs (TI-IFNs) drive immune effector functions during acute viral infections and regulate cell cycling and systemic metabolism. That said, chronic TI-IFN signaling in the context of HIV infection treated with antiretroviral therapy (ART) also facilitates viral persistence, in part by promoting immunosuppressive responses and CD8+ T cell exhaustion. To determine whether inhibition of IFN-α might provide benefit in the setting of chronic, ART-treated SIV infection of rhesus macaques, we administered an anti–IFN-α antibody followed by an analytical treatment interruption (ATI). IFN-α blockade was well-tolerated and associated with lower expression of TI-IFN–inducible genes (including those that are antiviral) and reduced tissue viral DNA (vDNA). The reduction in vDNA was further accompanied by higher innate proinflammatory plasma cytokines, expression of monocyte activation genes, IL-12–induced effector CD8+ T cell genes, increased heme/metabolic activity, and lower plasma TGF-β levels. Upon ATI, SIV-infected, ART-suppressed nonhuman primates treated with anti–IFN-α displayed lower levels of weight loss and improved erythroid function relative to untreated controls. Overall, these data demonstrated that IFN-α blockade during ART-treated SIV infection was safe and associated with the induction of immune/erythroid pathways that reduced viral persistence during ART while mitigating the weight loss and anemia that typically ensue after ART interruption.

Authors

Louise A. Swainson, Ashish Arunkumar Sharma, Khader Ghneim, Susan Pereira Ribeiro, Peter Wilkinson, Richard M. Dunham, Rebecca G. Albright, Samson Wong, Jacob D. Estes, Michael Piatak, Steven G. Deeks, Peter W. Hunt, Rafick-Pierre Sekaly, Joseph M. McCune

×

Figure 2

IFN-α blockade leads to a downregulation of innate antiviral genes, plasma TGF-β levels, and TI-IFN–inducible gene sets and upregulation of antigen presentation, IL-1, IL-12 signaling cascades, and effector CD8+ T cell signatures.

Options: View larger image (or click on image) Download as PowerPoint
IFN-α blockade leads to a downregulation of innate antiviral genes, plas...
(A) Heatmap showing leading-edge genes of immune genesets (40,43) that are significantly associated with reduction in LN vDNA (GSEA results in Supplemental Table 4; P < 0.05) and increase in cytokine cluster 5. (B) In conjunction with the systemic downregulation of antiviral genes with anti–IFN-α treatment, immunohistochemistry staining shows the downregulation of the prototypical antiviral protein, Mx1, in lymph nodes 9 weeks after anti–IFN-α (vs. control arm; Mann-Whitney U test, **P < 0.01). (C) Leading-edge genes from 2 effector CD8+ T cell signatures (GSE40666: defining effector vs. naive CD8+ T cell expression signatures and GSE15930: defining CD8+ T cell signatures induced after IL-12 treatment in vitro) were enriched after IFN-α blockade and associated with a decline in LN vDNA and a decrease in antiinflammatory cluster 4 cytokine levels (Supplemental Table 6). (D) Correlation network between nodes that represent change in LN vDNA, cytokine clusters, and SLEA (75) scores of intersecting leading-edge genes resulting from GSEA (38) against the 2 main outcomes (i.e., group comparison anti–IFN-α vs. control and change in LN vDNA). Node colors (in all nodes except LN vDNA and cytokine scores) represent change in SLEA scores between anti–IFN-α treatment and control groups at week 29 (red and blue represent increase and decrease in anti–IFN-α-treated groups, respectively). Edges represent correlations (ρ values calculated after Spearman’s test; edges with P < 0.05 shown) between nodes, where edges directly connected with LN vDNA are thickened to show direct correlates of the outcome of interest. Unless indicated, significant changes in NHP specimens between the 2 arms (n = 6/arm) 29 weeks after study initiation were assessed using the statistical tests indicated.

Copyright © 2022 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts